Annual report
7129.TEDINET S100OG2Y
Period2021-10-01 → 2022-03-31
Filed2022-06-27
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 38
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥19.5bn | 2021-10-01 → 2022-03-31 | Cons. | Net sales |
| Operating income | ¥186m | 2021-10-01 → 2022-03-31 | Cons. | Operating income |
| Ordinary income | ¥190m | 2021-10-01 → 2022-03-31 | Cons. | Ordinary income |
| Profit before tax | ¥534m | 2021-10-01 → 2022-03-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥292m | 2021-10-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥292m | 2021-10-01 → 2022-03-31 | Cons. | Profit loss |
| Total assets | ¥14.2bn | at 2022-03-31 | Cons. | Assets |
| Total liabilities | ¥11.0bn | at 2022-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥3.2bn | at 2022-03-31 | Cons. | Net assets |
| Net assets / equity | ¥3.0bn | at 2021-09-30 | Cons. | Net assets |
| Cash and deposits | ¥1.1bn | at 2022-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥1.1bn | at 2022-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥691m | at 2021-09-30 | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥919m | 2021-10-01 → 2022-03-31 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥2.5bn | 2021-10-01 → 2022-03-31 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | ¥2.0bn | 2021-10-01 → 2022-03-31 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥117.49 | 2021-10-01 → 2022-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥116.61 | 2021-10-01 → 2022-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| Net assets per share | ¥1,287.13 | at 2022-03-31 | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 22.5% | at 2022-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 9.4% | 2021-10-01 → 2022-03-31 | Cons. | Rate of return on equity (5-year summary) |
| Employees | 1,752 | at 2022-03-31 | Cons. | Number of employees |
| Revenue | ¥116m | 2021-10-01 → 2022-03-31 | Standalone | Operating revenue1 |
| Operating income | ¥52m | 2021-10-01 → 2022-03-31 | Standalone | Operating income |
| Ordinary income | ¥52m | 2021-10-01 → 2022-03-31 | Standalone | Ordinary income |
| Profit before tax | ¥52m | 2021-10-01 → 2022-03-31 | Standalone | Income before income taxes |
| Net income | ¥62m | 2021-10-01 → 2022-03-31 | Standalone | Profit loss |
| Total assets | ¥3.1bn | at 2022-03-31 | Standalone | Assets |
| Total liabilities | ¥71m | at 2022-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥3.1bn | at 2022-03-31 | Standalone | Net assets |
| Cash and deposits | ¥3m | at 2022-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥24.86 | 2021-10-01 → 2022-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥24.68 | 2021-10-01 → 2022-03-31 | Standalone | Diluted earnings per share (5-year summary) |
| Dividend per share | ¥17 | 2021-10-01 → 2022-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥1,232.94 | at 2022-03-31 | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 97.7% | at 2022-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 2.0% | 2021-10-01 → 2022-03-31 | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 2,488,300 | at 2022-03-31 | Standalone | Total number of issued shares (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 48
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | capex | 2021-10-01 → 2022-03-31 | ¥237,000 |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | depreciation | 2021-10-01 → 2022-03-31 | ¥4m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | employees | at 2022-03-31 | 22 pure |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2021-10-01 → 2022-03-31 | ¥932m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2021-10-01 → 2022-03-31 | ¥905m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2021-10-01 → 2022-03-31 | ¥27m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment assets | at 2022-03-31 | ¥165m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2021-10-01 → 2022-03-31 | ¥39m |
| Reconciling Itemsreconciling | capex | 2021-10-01 → 2022-03-31 | ¥218m |
| Reconciling Itemsreconciling | depreciation | 2021-10-01 → 2022-03-31 | ¥42m |
| Reconciling Itemsreconciling | revenue | 2021-10-01 → 2022-03-31 | −¥27m |
| Reconciling Itemsreconciling | revenue intersegment | 2021-10-01 → 2022-03-31 | −¥27m |
| Reconciling Itemsreconciling | segment assets | at 2022-03-31 | ¥2.0bn |
| Reconciling Itemsreconciling | segment profit | 2021-10-01 → 2022-03-31 | −¥798m |
| Medicine Businessreportable segment | capex | 2021-10-01 → 2022-03-31 | ¥175m |
| Medicine Businessreportable segment | depreciation | 2021-10-01 → 2022-03-31 | ¥68m |
| Medicine Businessreportable segment | employees | at 2022-03-31 | 194 pure |
| Medicine Businessreportable segment | revenue | 2021-10-01 → 2022-03-31 | ¥8.8bn |
| Medicine Businessreportable segment | revenue external | 2021-10-01 → 2022-03-31 | ¥8.8bn |
| Medicine Businessreportable segment | segment assets | at 2022-03-31 | ¥2.9bn |
| Medicine Businessreportable segment | segment profit | 2021-10-01 → 2022-03-31 | ¥559m |
| Nursing Care Businessreportable segment | capex | 2021-10-01 → 2022-03-31 | ¥69m |
| Nursing Care Businessreportable segment | depreciation | 2021-10-01 → 2022-03-31 | ¥55m |
| Nursing Care Businessreportable segment | employees | at 2022-03-31 | 290 pure |
| Nursing Care Businessreportable segment | revenue | 2021-10-01 → 2022-03-31 | ¥3.4bn |
| Nursing Care Businessreportable segment | revenue external | 2021-10-01 → 2022-03-31 | ¥3.4bn |
| Nursing Care Businessreportable segment | segment assets | at 2022-03-31 | ¥1.2bn |
| Nursing Care Businessreportable segment | segment profit | 2021-10-01 → 2022-03-31 | ¥25m |
| Nurturing Businessreportable segment | capex | 2021-10-01 → 2022-03-31 | ¥2.6bn |
| Nurturing Businessreportable segment | depreciation | 2021-10-01 → 2022-03-31 | ¥307m |
| Nurturing Businessreportable segment | employees | at 2022-03-31 | 1192 pure |
| Nurturing Businessreportable segment | revenue | 2021-10-01 → 2022-03-31 | ¥6.4bn |
| Nurturing Businessreportable segment | revenue external | 2021-10-01 → 2022-03-31 | ¥6.4bn |
| Nurturing Businessreportable segment | segment assets | at 2022-03-31 | ¥7.8bn |
| Nurturing Businessreportable segment | segment profit | 2021-10-01 → 2022-03-31 | ¥362m |
| —segment total | capex | 2021-10-01 → 2022-03-31 | ¥2.9bn |
| —segment total | depreciation | 2021-10-01 → 2022-03-31 | ¥430m |
| —segment total | revenue | 2021-10-01 → 2022-03-31 | ¥18.6bn |
| —segment total | revenue external | 2021-10-01 → 2022-03-31 | ¥18.6bn |
| —segment total | segment assets | at 2022-03-31 | ¥12.0bn |
| —segment total | segment profit | 2021-10-01 → 2022-03-31 | ¥946m |
| Total Of Reportable Segments And Otherssegment total | capex | 2021-10-01 → 2022-03-31 | ¥2.9bn |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2021-10-01 → 2022-03-31 | ¥434m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2021-10-01 → 2022-03-31 | ¥19.5bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2021-10-01 → 2022-03-31 | ¥19.5bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2021-10-01 → 2022-03-31 | ¥27m |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2022-03-31 | ¥12.2bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2021-10-01 → 2022-03-31 | ¥985m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 794
| Item | Context | Value | Unit |
|---|---|---|---|
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E36714-000HaraMasaoMember | － | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant | 638900 | |
| Audit fees reporting company | CurrentYearDuration | 42000000 | JPY |
| Non audit fees reporting company | CurrentYearDuration | － | JPY |
| Audit fees consolidated subsidiaries | CurrentYearDuration | － | JPY |
| Non audit fees consolidated subsidiaries | CurrentYearDuration | － | JPY |
| Audit fees total | CurrentYearDuration | 42000000 | JPY |
| Non audit fees total | CurrentYearDuration | － | JPY |
| Total amount of remuneration etc remuneration etc by category of directors and other officers | CurrentYearDuration_jpcrp030000-asr_E36714-000DirectorsExcludingDirectorsWhoAreAuditAndSupervisoryCommitteeMembersMember | 113184000 | JPY |
| Base remuneration remuneration etc by category of directors and other officers | CurrentYearDuration_jpcrp030000-asr_E36714-000DirectorsExcludingDirectorsWhoAreAuditAndSupervisoryCommitteeMembersMember | 103080000 | JPY |
| Performance based remuneration remuneration by category of directors and other officers | CurrentYearDuration_jpcrp030000-asr_E36714-000DirectorsExcludingDirectorsWhoAreAuditAndSupervisoryCommitteeMembersMember | 10104000 | JPY |
| Number of directors and other officers remuneration etc by category of directors and other officers | CurrentYearDuration_jpcrp030000-asr_E36714-000DirectorsExcludingDirectorsWhoAreAuditAndSupervisoryCommitteeMembersMember | 6 | |
| Total amount of remuneration etc remuneration etc by category of directors and other officers | CurrentYearDuration_jpcrp030000-asr_E36714-000DirectorsAndAuditAndSupervisoryCommitteeMembersMember | 17460000 | JPY |
| Base remuneration remuneration etc by category of directors and other officers | CurrentYearDuration_jpcrp030000-asr_E36714-000DirectorsAndAuditAndSupervisoryCommitteeMembersMember | 17460000 | JPY |
| Performance based remuneration remuneration by category of directors and other officers | CurrentYearDuration_jpcrp030000-asr_E36714-000DirectorsAndAuditAndSupervisoryCommitteeMembersMember | － | JPY |
| Number of directors and other officers remuneration etc by category of directors and other officers | CurrentYearDuration_jpcrp030000-asr_E36714-000DirectorsAndAuditAndSupervisoryCommitteeMembersMember | 3 | |
| Total amount of remuneration etc remuneration etc by category of directors and other officers | CurrentYearDuration_jpcrp030000-asr_E36714-000ThereofOutsideDirectorsAndOtherOfficersMember | 14280000 | JPY |
| Base remuneration remuneration etc by category of directors and other officers | CurrentYearDuration_jpcrp030000-asr_E36714-000ThereofOutsideDirectorsAndOtherOfficersMember | 14280000 | JPY |
| Performance based remuneration remuneration by category of directors and other officers | CurrentYearDuration_jpcrp030000-asr_E36714-000ThereofOutsideDirectorsAndOtherOfficersMember | － | JPY |
| Number of directors and other officers remuneration etc by category of directors and other officers | CurrentYearDuration_jpcrp030000-asr_E36714-000ThereofOutsideDirectorsAndOtherOfficersMember | 4 | |
| Number of issues shares not listed investment shares held for purposes other than pure investment reporting company | CurrentYearInstant | 1 | |
| Carrying amount shares not listed investment shares held for purposes other than pure investment reporting company | CurrentYearInstant | 100000 | JPY |
| Number of issues shares other than those not listed investment shares held for purposes other than pure investment reporting company | CurrentYearInstant | － | |
| Carrying amount shares other than those not listed investment shares held for purposes other than pure investment reporting company | CurrentYearInstant | － | JPY |
| Number of issues whose number of shares increased shares not listed investment shares held for purposes other than pure investment reporting company | CurrentYearDuration | － | |
| Total acquisition cost for increased shares shares not listed investment shares held for purposes other than pure investment reporting company | CurrentYearDuration | － | JPY |
| Number of issues whose number of shares increased shares other than those not listed investment shares held for purposes other than pure investment reporting company | CurrentYearDuration | － | |
| Total acquisition cost for increased shares shares other than those not listed investment shares held for purposes other than pure investment reporting company | CurrentYearDuration | － | JPY |
| Number of issues whose number of shares decreased shares not listed investment shares held for purposes other than pure investment reporting company | CurrentYearDuration | － | |
| Total sale amount for decreased shares shares not listed investment shares held for purposes other than pure investment reporting company | CurrentYearDuration | － | JPY |
| Number of issues whose number of shares decreased shares other than those not listed investment shares held for purposes other than pure investment reporting company | CurrentYearDuration | － | |
| Total sale amount for decreased shares shares other than those not listed investment shares held for purposes other than pure investment reporting company | CurrentYearDuration | － | JPY |
| Cash and deposits | CurrentYearInstant | 1122652000 | JPY |
| Accounts receivable trade | CurrentYearInstant | 2309390000 | JPY |
| Merchandise | CurrentYearInstant | 362286000 | JPY |
| Supplies | CurrentYearInstant | 20500000 | JPY |
| Accounts receivable other | CurrentYearInstant | 630595000 | JPY |
| Other ca | CurrentYearInstant | 451308000 | JPY |
| Allowance for doubtful accounts ca | CurrentYearInstant | -2596000 | JPY |
| Current assets | CurrentYearInstant | 4894137000 | JPY |
| Buildings net | CurrentYearInstant | 5155388000 | JPY |
| Structures net | CurrentYearInstant | 96401000 | JPY |
| Tools furniture and fixtures net | CurrentYearInstant | 422175000 | JPY |
| Machinery equipment and vehicles net | CurrentYearInstant | 177000 | JPY |
| Land | CurrentYearInstant | 797750000 | JPY |
| Lease assets net ppe | CurrentYearInstant | 273913000 | JPY |
| Construction in progress | CurrentYearInstant | 31361000 | JPY |
| Property plant and equipment | CurrentYearInstant | 6777168000 | JPY |
| Leasehold right | CurrentYearInstant | 204360000 | JPY |
| Software | CurrentYearInstant | 38385000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |